Structure–activity relationship studies on 1-heteroaryl-3-phenoxypropan-2-ones acting as inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase: replacement of the activated ketone group by other serine traps

References

• Bachovchin DA, Cravatt BF. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov 2012;11:52–68
   PubMed Web of Science ®Google Scholar
• Long JZ, Cravatt BF. The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev 2011;111:6022–63
   PubMed Web of Science ®Google Scholar
• Dennis EA, Cao J, Hsu YH, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011;111:6130–85
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1–24
   PubMed Web of Science ®Google Scholar
• Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 2008;49:101–32
   PubMedGoogle Scholar
• Lehr M. Inhibitors of cytosolic phospholipase A2α as anti-inflammatory drugs. In: Levin JI, Laufer S, eds. Anti-inflammatory drug discovery. Cambridge: The Royal Society of Chemistry; 2012: 35–57
   Google Scholar
• Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010–present). Expert Opin Ther Pat 2013;23:333–44
   PubMed Web of Science ®Google Scholar
• Khanna IK, Alexander CW. Fatty acid amide hydrolase inhibitors – progress and potential. CNS Neurol Disord Drug Targets 2011;10:545–58
   PubMed Web of Science ®Google Scholar
• Bisogno T, Maccarrone M. Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Expert Opin Drug Discov 2013;8:509–22
   PubMed Web of Science ®Google Scholar
• Ludwig J, Bovens S, Brauch C, et al. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α. J Med Chem 2006;49:2611–20
   PubMed Web of Science ®Google Scholar
• Drews A, Bovens S, Roebrock K, et al. 1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. J Med Chem 2010;53:5165–78
   PubMed Web of Science ®Google Scholar
• Bovens S, Schulze Elfringhoff A, et al. 1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability. J Med Chem 2010;53:8298–308
   PubMed Web of Science ®Google Scholar
• Forster L, Ludwig J, Kaptur M, et al. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase. Bioorg Med Chem 2010;18:945–52
   PubMed Web of Science ®Google Scholar
• Zahov S, Drews A, Hess M, et al. 1-(3-Biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase. ChemMedChem 2011;6:544–9
   PubMed Web of Science ®Google Scholar
• Sundermann T, Fabian J, Hanekamp W, Lehr M. 1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability. Bioorg Med Chem 2015;23:2579–92
   PubMed Web of Science ®Google Scholar
• Connolly S, Bennion C, Botterell S, et al. Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton. J Med Chem 2002;45:1348–62
   PubMed Web of Science ®Google Scholar
• Fabian J, Hanekamp W, Thomas MH, et al. Investigations on the metabolic stability of cytosolic phospholipase A2α inhibitors with 1-indolylpropan-2-one structure. Chem Biol Interact 2013;206:356–63
   PubMed Web of Science ®Google Scholar
• Sundermann T, Arnsmann M, Schwarzkopf J, et al. Convergent and enantioselective syntheses of cytosolic phospholipase A2α inhibiting N-(1-indazol-1-ylpropan-2-yl)carbamates. Org Biomol Chem 2014;12:4021–30
   PubMed Web of Science ®Google Scholar
• Schwarzkopf J, Sundermann T, Arnsmann M, et al. Inhibitors of cytosolic phospholipase A2α with carbamate structure: synthesis, biological activity, metabolic stability, and bioavailability. Med Chem Res 2014;23:5250–62
   Web of Science ®Google Scholar
• Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med Chem 2010;2:949–64
   PubMed Web of Science ®Google Scholar
• Li J, Wilk E, Wilk S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch Biochem Biophys 1995;323:148–54
   PubMed Web of Science ®Google Scholar
• Porte AM, van der Donk WA, Burgess K. New and efficient synthesis of an amino acid for preparing phosphine-functionalized peptidomimetics. J Org Chem 1998;63:5262–4
   Web of Science ®Google Scholar
• Wu W, Li R, Malladi SS, et al. Structure–activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J Med Chem 2010;53:3198–213
   PubMed Web of Science ®Google Scholar
• Hanekamp W, Lehr M. Determination of arachidonic acid by on-line solid-phase extraction HPLC with UV detection for screening of cytosolic phospholipase A2α inhibitors. J Chromatogr B 2012;900:79–84
   PubMed Web of Science ®Google Scholar
• Holtfrerich A, Hanekamp W, Lehr M. (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Eur J Med Chem 2013;63:64–75
   PubMed Web of Science ®Google Scholar
• Forster L, Schulze Elfringhoff A, Lehr M. High-performance liquid chromatographic assay with fluorescence detection for the evaluation of inhibitors against fatty acid amide hydrolase. Anal Bioanal Chem 2009;394:1679–85
   PubMed Web of Science ®Google Scholar
• Boger DL, Sato H, Lerne AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97:5044–9
   PubMed Web of Science ®Google Scholar
• Katritzky AR, Vakulenko AV, Akue-Gedu R, et al. Regiospecific preparation of 1,4,5-trisubstituted pyrazoles from 2-(1H-1,2,3-benzotriazol-1-yl)-3-(4-aryl)-2-propenals. Arkivoc 2007;i:9–21
   Google Scholar
• Sundermann T, Lehr M. Synthesis of 1-tetrazolylalkan-2-amines and –carbamates. Synth Commun 2014;44:1641–8
   Web of Science ®Google Scholar
• McKew JC, Foley MA, Thakker P, et al. Inhibition of cytosolic phospholipase A2α: hit to lead optimization. J Med Chem 2006;49:135–58
   PubMed Web of Science ®Google Scholar
• Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76–81
   PubMed Web of Science ®Google Scholar